Showing 2511-2520 of 3039 results for "".
- Robert Califf Confirmed to Lead FDA for Second Timehttps://modernod.com/news/robert-califf-confirmed-to-lead-fda-for-second-time/2480645/The US Senate on Tuesday voted 50 to 46 in favor of confirming President Joe Biden nominee Robert Califf as commissioner of the FDA, a position he previously held under the Obama administration, according to a FiercePharma report.&
- Alimera Sciences Announces Launch of Iluvien for Uveitis in Spainhttps://modernod.com/news/alimera-sciences-announces-launch-of-iluvien-for-uveitis-in-spain/2480619/Alimera Sciences announced that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, will launch Iluvien for noninfectious posterior uveitis in Spain, through its distribution partner, Brill Pharma (Brill). Brill has received a positive resolution fo
- Maintaining Transparency: Study to Focus on Causes of Cataractshttps://modernod.com/news/maintaining-transparency-study-to-focus-on-causes-of-cataracts/2480616/Researchers at the University of Arizona College of Medicine – Tucson are leading a study to identify the biological mechanisms that cause cataracts in the hopes that new, nonsurgical treatments may be developed. Nicholas Delame
- Tarsus Appoints José Trevejo, MD, PhD, Chief Medical Officerhttps://modernod.com/news/tarsus-appoints-jose-trevejo-md-phd-chief-medical-officer/2480613/Tarsus Pharmaceuticals announced the appointment of José Trevejo, MD, PhD, as Chief Medical Officer. Dr. Trevejo brings over 20 years of experience advancing the clinical development of novel therapeutics for serious diseases. Dr. Trevejo’s leadership will be highly valued
- Foundation Fighting Blindness Promotes Jason Menzo to President and Chief Operating Officerhttps://modernod.com/news/foundation-fighting-blindness-promotes-jason-menzo-to-president-and-chief-operating-officer/2480580/The Foundation Fighting Blindness announced the promotion of Jason Menzo to president and chief operating officer, effective immediately. Since joining the Foundation in 2018, Mr. Menzo has had a profound positive impact on redefining the non-profit’s operations, includi
- Kriya Expands Gene Therapy Pipeline and Establishes Its Rare Disease Therapeutic Area Division with Acquisition of Warden Biohttps://modernod.com/news/kriya-expands-gene-therapy-pipeline-and-establishes-its-rare-disease-therapeutic-area-division-with-the-acquisition-of-warden-bio/2480550/Gene therapy company Kriya Therapeutics announced that it has acquired Warden Bio, a company developing novel AAV-mediated gene therapies for glycogen storage disorders (GSDs). Under the agreement, Kriya has obtained exclusive rights to Warden Bio’s five preclinical gene therapy programs.</
- CoFi: The Latest in Co‑Management Best Practiceshttps://modernod.com/news/the-latest-in-comanagement-best-practices/2480541/Throughout ophthalmology, there is increasing awareness of allegations of non-compliance with the federal Anti-Kickback Statute when surgical practices co‑manage patients of premium IOL, LASIK, RLE, and other procedures with optometry practices, according to CoFi, a provider of payment solutions
- Haag-Streit to Focus on Surgical Microscopes in Ophthalmologyhttps://modernod.com/news/haag-streit-to-focus-on-surgical-microscopes-in-ophthalmology/2480524/Haag-Streit announced that it was focus its business moving forward on ophthalmology—discontinuting its surgical product portfolio in neurosurgery, spine surgery, ENT and plastic-reconstructive surgery. "For our customers, this focus on eye care will allow us to offer so
- LayerBio Granted U.S. Patent for OcuRing Drug Delivery Platformhttps://modernod.com/news/layerbio-granted-us-patent-for-ocuring-drug-delivery-platform/2480486/LayerBio announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 11,185,441. "This patent issuance marks an important milestone for the OcuRing platform and recognition of novelty and uniqueness of our drug delivery technology,&
- Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of Brimochol for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-announces-positive-topline-clinical-data-from-phase-2-vivid-study-of-brimochol-for-the-treatment-of-presbyopia/2480481/Visus Therapeutics reported positive topline results from VIVID, the company’s phase 2 study of three novel topical ophthalmic formulations under investigation for the treatment of presbyopia. All three investigational candidates studied in VIVID achieved the endpoint of 3 lines of improvem